AU2008341112B2 - Pre-surgical treatment - Google Patents

Pre-surgical treatment Download PDF

Info

Publication number
AU2008341112B2
AU2008341112B2 AU2008341112A AU2008341112A AU2008341112B2 AU 2008341112 B2 AU2008341112 B2 AU 2008341112B2 AU 2008341112 A AU2008341112 A AU 2008341112A AU 2008341112 A AU2008341112 A AU 2008341112A AU 2008341112 B2 AU2008341112 B2 AU 2008341112B2
Authority
AU
Australia
Prior art keywords
surgical procedure
pharmaceutical composition
brimonidine
patient
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008341112A
Other languages
English (en)
Other versions
AU2008341112A1 (en
Inventor
Jack A. Dejovin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma SA
Original Assignee
Galderma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma SA filed Critical Galderma SA
Publication of AU2008341112A1 publication Critical patent/AU2008341112A1/en
Assigned to GALDERMA LABORATORIES, INC. reassignment GALDERMA LABORATORIES, INC. Amend patent request/document other than specification (104) Assignors: GALDERMA LABORATORIES. INC.
Application granted granted Critical
Publication of AU2008341112B2 publication Critical patent/AU2008341112B2/en
Assigned to GALDERMA S.A. reassignment GALDERMA S.A. Request for Assignment Assignors: GALDERMA LABORATORIES, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AU2008341112A 2007-12-21 2008-12-17 Pre-surgical treatment Ceased AU2008341112B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1591207P 2007-12-21 2007-12-21
US61/015,912 2007-12-21
PCT/US2008/013797 WO2009082452A1 (en) 2007-12-21 2008-12-17 Pre-surgical treatment

Publications (2)

Publication Number Publication Date
AU2008341112A1 AU2008341112A1 (en) 2009-07-02
AU2008341112B2 true AU2008341112B2 (en) 2014-02-06

Family

ID=40801507

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008341112A Ceased AU2008341112B2 (en) 2007-12-21 2008-12-17 Pre-surgical treatment

Country Status (10)

Country Link
US (1) US20110224215A1 (enExample)
EP (1) EP2230910A4 (enExample)
JP (1) JP5580210B2 (enExample)
KR (1) KR20100099191A (enExample)
CN (1) CN101902913B (enExample)
AU (1) AU2008341112B2 (enExample)
BR (1) BRPI0822095A2 (enExample)
CA (1) CA2709199A1 (enExample)
NZ (1) NZ586302A (enExample)
WO (1) WO2009082452A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
EP3498299A1 (en) 2007-11-16 2019-06-19 Aclaris Therapeutics, Inc. Compositions and methods for treating purpura
US9050246B2 (en) * 2009-05-29 2015-06-09 Galderma Research & Development Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
US8513247B2 (en) * 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
KR20150058551A (ko) 2010-03-26 2015-05-28 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
EP2605753A2 (en) * 2010-10-21 2013-06-26 Galderma S.A. Topical gel composition
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
PH12013500738A1 (en) * 2010-10-21 2016-08-05 Galderma Sa Brimonidine gel compositions and methods of use
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
MX2014004383A (es) 2011-10-19 2014-11-12 Galderma Sa Metodo para reducir el enrojecimiento facial asociado con el uso sistemico de inhibidores de fosfodiesterasa tipo 5.
JP6339364B2 (ja) * 2013-12-27 2018-06-06 カズマパートナーズ株式会社 無定形ブリモニジン酒石酸塩及びその製造方法
WO2019083771A1 (en) * 2017-10-23 2019-05-02 Microcures, Inc. METHOD FOR IMPROVING THE RECOVERY OF A SKIN TREATED WITH A COSMETIC LASER

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92351A (en) 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2154979A1 (en) * 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
EP3498299A1 (en) * 2007-11-16 2019-06-19 Aclaris Therapeutics, Inc. Compositions and methods for treating purpura

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Fuchs P N et al: "Heat, but not mechanical hyperalgesia, following adrenergic injections in normal human skin" *
Hong et al: "Effect of Prophylactic Brimonidine Instillation on Bleeding During Strabismus Srgery in Adults" *
Kratz A et al: "Controlling bleeding from superficial wounds by the use of topical alpha adrenoreceptor agonists spray - A randomized, masked, controlled study" *

Also Published As

Publication number Publication date
US20110224215A1 (en) 2011-09-15
CA2709199A1 (en) 2009-07-02
CN101902913A (zh) 2010-12-01
WO2009082452A1 (en) 2009-07-02
CN101902913B (zh) 2014-06-18
AU2008341112A1 (en) 2009-07-02
BRPI0822095A2 (pt) 2014-10-07
KR20100099191A (ko) 2010-09-10
NZ586302A (en) 2013-03-28
EP2230910A4 (en) 2011-04-13
JP2011507845A (ja) 2011-03-10
JP5580210B2 (ja) 2014-08-27
EP2230910A1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
US20110224215A1 (en) Pre-surgical treatment
DK2388007T3 (en) TOPICAL PREPARATION FOR USE IN THE TREATMENT OF rosacea-INDUCED redness
US20120295914A1 (en) Combination of adrenergic receptor agonist alpha-1 or alpha-2, preferably brimonidine with fillers, preferably hyaluronic acid
US20120040016A1 (en) Brimonidine compositions for treating erythema
US20150313894A1 (en) Combination treatment for rosacea
AU2012324544B2 (en) Method for treating capillary hemangiomas
JP2016525553A (ja) 皮膚肥厚の治療法
US20140329874A1 (en) Alpha adrenergic agonists for the treatment of tissue trauma
CA2850273A1 (en) Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
US10039770B2 (en) Prostaglandin F2Alpha and analogues thereof for treating atrophic cutaneous scarring
HK1204996B (en) Compounds, formulations, and methods for treating or preventing rosacea

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GALDERMA S.A.

Free format text: FORMER APPLICANT(S): GALDERMA LABORATORIES, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired